Ocular tolerance of bacillus Calmette-Guerin organisms.

The results of this investigation indicate that 5 X 10(6) and 5 X 10(8) viable bacillus Calmette-Guerin (BCG) organisms (Mycobacterium bovis strain) can be safely administered in the subconjunctival region of the eye of New Zealand albino rabbits without producing toxic effects locally or within the eye. This study provides a format for testing the applicability of BCG immunotherapy for experimental melanomas.

[1]  D. Morton,et al.  Adjuvant immunotherapy with BCG in treatment of regional-lymph-node metastases from malignant melanoma. , 1976, The New England journal of medicine.

[2]  E. Hersh,et al.  BCG Stimulation of Immune Responsiveness in Patients with Malignant Melanoma , 1974 .

[3]  Baldwin Rw,et al.  BCG immunotherapy of rat tumors of defined immunogenicity. , 1973 .

[4]  G. Mathé,et al.  BCG in cancer immunotherapy: results obtained with various BCG preparations in a screening study for systemic adjuvants applicable to cancer immunoprophylaxis or immunotherapy. , 1973, National Cancer Institute monograph.

[5]  P. Alexander.  Activated macrophages and the antitumor action of BCG. , 1973, National Cancer Institute monograph.

[6]  Y. Hirshaut,et al.  Treatment of malignant melanoma by intratumoral injection of BCG. , 1973, National Cancer Institute monograph.

[7]  B. Zbar,et al.  Immunologic approaches to various types of cancer with the use of BCG and purified protein derivatives. , 1973, National Cancer Institute monograph.

[8]  E. Hersh,et al.  BCG stimulation of immune responsiveness in patients with malignant melanoma. Preliminary report , 1973, Cancer.

[9]  I. Gery,et al.  On the mode of action of BCG. , 1973, Nature: New biology.

[10]  B. Zbar.  Tumor regression mediated by Mycobacterium bovis (strain BCG). , 1972, National Cancer Institute monograph.

[11]  L. Nathanson.  Regression of intradermal malignant melanoma after intralesional injection of Mycobacterium bovis strain BCG. , 1972, Cancer chemotherapy reports.

[12]  H. Seigler,et al.  Non-specific and specific immunotherapy in patients with melanoma , 1972 .

[13]  Ikonopisov Rl.  The rationale of immunostimulation procedures in the therapeutic approach to malignant melanoma of the skin. , 1972 .

[14]  G. Casale,et al.  Tumor cell destruction by macrophages. , 1972, Journal of medicine.

[15]  D. Morton,et al.  Immunological aspects of neoplasia: a rational basis for immunotherapy. , 1971, Annals of internal medicine.

[16]  D. Morton,et al.  Immunological factors which influence response to immunotherapy in malignant melanoma. , 1970, Surgery.